Liver Toxicity in Rheumatoid Arthritis Patients Treated With Methotrexate
Authors
Abstract:
Background:Methotrexate (MTX) is one of the most commonly used disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis (RA) which can be associated with toxic effects on different organs. This study was designed to investigate the hepatotoxic effects in RA patients treated with MTX. Methods: In this cross-sectional observational study, RA patients who received standard dose regimen of methotrexate (7.5-15 mg/week) for a minimum of 3 months were included. Liver function parameters including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and albumin as well as prothrombin time (PT) were assessed for all patients. The patients were divided into two groups according to the MTX dose received: (1) low-dose group (≤ 7.5 mg/week) and (2) high-dose group (> 7.5 mg/week). Results:One-hundred patients (64% women) with mean age of 45.8 ± 7.5 years were studied. Eighty patients (80%) received low-dose MTX and the rest received high-dose MTX. Mean values of AST (P = 0.004), ALT (P = 0.001) and PT (P = 0.014) were significantly higher in patients receiving high-dose MTX compared with those who received low-dose MTX. Mean serum albumin was significantly lower in high-dose MTX receiving patients (P = 0.014). Moreover, elevated AST (RR (95% CI): 4.3 (2.1-8.7), P < 0.001), increased ALT (RR (95% CI): 4.9 (2.4-9.9), P < 0.001), and hypoalbuminemia (RR (95% CI): 2.3 (1.1-4.7), P = 0.030) were significantly more common in patients treated with high-dose MTX. The liver parameters restored to normal values after discontinuation of the treatment. Conclusion:MTX therapy especially in doses higher than 7.5 mg/week can be associated with increased risk for hepatotoxic effects. Regular monitoring for patients under MTX treatment is necessary.
similar resources
liver toxicity in rheumatoid arthritis patients treated with methotrexate
background:methotrexate (mtx) is one of the most commonly used disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis (ra) which can be associated with toxic effects on different organs. this study was designed to investigate the hepatotoxic effects in ra patients treated with mtx. methods: in this cross-sectional observational study, ra patients who received standard do...
full textPurine enzymes in patients with rheumatoid arthritis treated with methotrexate.
OBJECTIVES To study (a) purine metabolism during treatment with methotrexate (MTX) in patients with rheumatoid arthritis (RA) and (b) the relation of purine metabolism with efficacy and toxicity of MTX treatment. METHODS One hundred and three patients with active RA who started treatment with MTX were included. The initial MTX dosage was 7.5 mg/week and raised to a maximum of 25 mg weekly if ...
full textmethotrexate hepatotoxicity in patients with rheumatoid arthritis
background increases in aminotransferases (transaminitis) are potential major adverse reactions seen with long-term use of methotrexate (mtx). the aim of this study, therefore was to evaluate the incidence of mtx induced hepatotoxicity and its risk factors among rheumatoid arthritis (ra) patients. methods this retrospective study described 286 patients with ra who received ≤ 7.5 mg mtx weekly...
full textRemaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate
OBJECTIVE To investigate the frequency of remaining pain in early rheumatoid arthritis (RA) after 3 months of treatment with methotrexate as the only disease modifying antirheumatic drug, with a special focus on patients with a good clinical response. METHODS The study base was cases reported to a population-based early RA cohort who had followup data from the Swedish Rheumatology Quality Reg...
full textMortality in rheumatoid arthritis patients treated with or without methotrexate.
BACKGROUND Rheumatoid arthritis (RA) is a chronic disease associated with excess mortality. In 1974 a registry of RA patients was established at the Wichita Arthritis Center. It has been directed by its founder, Dr. Frederick Wolfe, ever since. The database for RA patients provided results for the present study and 1 of the 4 series reported previously. RESULTS These are based on a consecutiv...
full textLiver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate.
OBJECTIVE Some studies have reported that adding leflunomide (LEF) to the treatment of rheumatoid arthritis (RA) in patients who do not respond to methotrexate (MTX) improved efficacy but increased the risk of liver toxicity. This study aimed at assessing the incidence of liver toxicity in patients with active RA using the LEF and MTX combination therapy in comparison with that of patients on M...
full textMy Resources
Journal title
volume 4 issue 3
pages 102- 105
publication date 2015-09-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023